Азитромицин при ковиде

chuka_lis — 05.08.2021 — Коронавирус Системный мета-анализ публикаций по  применению азитромицина для лечения ковидных больных  в разных странах (Бразилия,Франция, Италия, Турция, Англия, США, Иран, Испания)  показал, что  нет отличий между теми группами, которые принимали антибиотик или нет, по таким показателям, как смертность от ковида, и длительность пребывания в больнице, тяжести течения болезни, необходмости в реанимации или ИВЛ, и тд.
В финальный анализ вошли данные по 23 тыс больным.
Но так же не было и найдено, что от применения азитромицина были и побочные эффекты (вроде сердечных).
Просто был неэффективен.
Background: Azithromycin (AZM) has been widely used in the management of Covid-19. However, the evidence on its actual effects remains disperse and difficult to apply in clinical settings. This systematic review and metanalysis summarizes the studies on the beneficial and adverse effect of AZM in patients with Covid-19. Methods: The PRISMA 2020 statement criteria were followed. Randomized controlled trials (RCTs) and observational studies comparing clinical outcomes of patients treated, and not treated, with AZM, indexed until the 5th of July 2021, were searched in PubMed, Embase, The Web of Science, Scopus, The Cochrane Central Register of Controlled Trials, and MedRXivs. ..Finally, 16 studies, five RCTs and 11 with an observational design, with a total of 22984 patients, were included. The metanalysis showed no difference in mortality for those treated, or not, with AZM, OR: 0.95 (0.79-1.13). There was also no significant difference for those treated, and not, with AZM in need for hospital admission or time to admission from ambulatory settings, clinical severity, need for intensive care, or adverse effects. Conclusions: These results presented in this review do not support the use of AZM in the management of Covid-19. They also show that any harm caused to the patient who received it is unlikely. Future research on treatment for patients with Covid-19 may need to focus on other drugs
This systematic review and metanalysis presents strong evidence on the lack of association between AZM and any clinical benefit.34 This evidence is consistent across 16 studies conducted in Europe, America and Asia with diverse methodology and design. There is also no evidence of AZM being associated with any serious adverse events, including cardiovascular disease. The results presented in this review do not support the use of AZM in the management of Covid-19. They also show that any harm caused to patients who received it is unlikely, which would be consistent with the well stablished safety profile reported before for AZM.

Оставить комментарий

Популярные посты:

• Ранее
• Архив